Literature DB >> 28119133

Breast cancer metabolic cross-talk: Fibroblasts are hubs and breast cancer cells are gatherers of lipids.

Filipa Lopes-Coelho1, Saudade André2, Ana Félix2, Jacinta Serpa3.   

Abstract

The cellular components of microenvironment are partners of cancer cells, sharing soluble factors and organic molecules to accomplish tumor energy and biomass demands. We tested the role of fibroblasts in fatty acids metabolism in breast cancer, addressing fatty acid synthase (FASN) expression and activity, the expression of lipids chaperons (FABPs) and transporters (FATPs) and lipids cellular content. We showed that the amount of lipids increased in cancer cells exposed to fibroblasts conditioned media, showing that lipids transfer is crucial in this metabolic cross-talk. Accordingly, it was seen in those cancer cells a concomitant decrease in the expression of FABP2 and FABP3 and an increase in FATP1 expression, whose function is independent of FABPs. The in vivo experiment corroborates the role of CAFs in tumor growth. Our study is one more step toward the understanding of metabolic dynamics between cancer cells and CAFs, disclosing FATP1 as a putative target to disturb the transfer of lipids between CAFs and breast cancer cells.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; CAFs; FASN; FATP1; Metabolic cross-talk; Metabolic fitness; Microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28119133     DOI: 10.1016/j.mce.2017.01.031

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  23 in total

Review 1.  Lipid Metabolism in Tumor-Associated Fibroblasts.

Authors:  Hongzhong Li; Jingyuan Wan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Lipid metabolism and lipophagy in cancer.

Authors:  Meenu Maan; Jeffrey M Peters; Mainak Dutta; Andrew D Patterson
Journal:  Biochem Biophys Res Commun       Date:  2018-02-10       Impact factor: 3.575

Review 3.  Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance.

Authors:  Pritish Nilendu; Sachin C Sarode; Devashree Jahagirdar; Ishita Tandon; Shankargouda Patil; Gargi S Sarode; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cell Oncol (Dordr)       Date:  2018-07-19       Impact factor: 6.730

Review 4.  Advances in Analyzing the Breast Cancer Lipidome and Its Relevance to Disease Progression and Treatment.

Authors:  Ashley V Ward; Steven M Anderson; Carol A Sartorius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-12-16       Impact factor: 2.673

Review 5.  Lipids in the tumor microenvironment: From cancer progression to treatment.

Authors:  Kevin C Corn; McKenzie A Windham; Marjan Rafat
Journal:  Prog Lipid Res       Date:  2020-08-11       Impact factor: 16.195

Review 6.  Overview: Lipid Metabolism in the Tumor Microenvironment.

Authors:  Kaili Ma; Lianjun Zhang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Interactions in the (Pre)metastatic Niche Support Metastasis Formation.

Authors:  Ginevra Doglioni; Sweta Parik; Sarah-Maria Fendt
Journal:  Front Oncol       Date:  2019-04-24       Impact factor: 6.244

8.  Unraveling FATP1, regulated by ER-β, as a targeted breast cancer innovative therapy.

Authors:  Cindy Mendes; Filipa Lopes-Coelho; Cristiano Ramos; Filipa Martins; Inês Santos; Armanda Rodrigues; Fernanda Silva; Saudade André; Jacinta Serpa
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

Review 9.  Cancer-associated adipocytes: key players in breast cancer progression.

Authors:  Qi Wu; Bei Li; Zhiyu Li; Juanjuan Li; Si Sun; Shengrong Sun
Journal:  J Hematol Oncol       Date:  2019-09-10       Impact factor: 17.388

Review 10.  Metabolic Reprogramming in Triple-Negative Breast Cancer.

Authors:  Xiangyu Sun; Mozhi Wang; Mengshen Wang; Xueting Yu; Jingyi Guo; Tie Sun; Xinyan Li; Litong Yao; Haoran Dong; Yingying Xu
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.